Book a no-commitment consultation to see how bit.bio cells can accelerate your research and drug discovery. To redeem, include the correct promo code with your submission below—find it listening to The Biotech Startups Podcast.
bit.bio provides a range of deterministically programmed, human iPSC derived cells for drug discovery and research. These products include wild type cell, disease model cells and CRISPR ready cells.
Find out more about our ioCells here: https://www.bit.bio/discover-iocells
bit.bio has the ability to create any human cell type and manufacture it with consistency at scale. This unlocks unparalleled opportunities in cell therapy. The possibilities for novel cures are endless.
Discover more about bit.bio's cell therapy pipeline here: https://www.bit.bio/therapeutics-pipeline
With Nobel Prize-winning science underpinning bit.bio's understanding of cell identity as defined by unique combinations of transcription factors, their deterministic cell programming technology, opti-ox, enables conversion of induced pluripotent stem cells (iPSCs) into any desired human cell type in a single step. This is achieved within days and at industrial scale, while maintaining exceptional purity and consistency.
bit.bio is creating highly differentiated human cell products for research and drug discovery (ioCells) and cell therapy (txCells). Their growing commercial ioCells portfolio comprises ioWild Type Cells, ioDisease Model Cells and ioCRISPR-Ready Cells. bit.bio's cell therapy pipeline is currently focused on metabolism and endocrinology, immunology and neurology therapeutic areas.
Their lead candidate, bbHEP01 (encapsulated allogeneic txHepatocytes), is in development for acute liver diseases. Additionally, bit.bio is collaborating with BlueRock Therapeutics (a wholly owned independently operated subsidiary of Bayer AG) on regulatory T cell (Treg)-based cell therapies.
bit.bio, a synthetic biology company, is democratizing human cells to advance biomedical research and enable transformative treatments. bit.bio utilizes opti-ox technology to deterministically program induced pluripotent stem cells (iPSCs)into any desired human cell type in a single step, within days at an industrial scale, with exceptional purity and consistency. Their growing portfolio includes cells which are used for research and drug discovery (ioCells) and cell therapy (txCells).
Are you an Excedr client or a listener of The Biotech Startups Podcast? Unlock exclusive rewards and savings designed to help your business scale and thrive. Fill out the form below to explore partner discounts and benefits tailored to your growth.
